| Lan, Xiaoli |
NCT05542953: [18F]APN-1607 PET in Subjects With AD Compared to HC |
|
|
| Recruiting | 3 | 230 | RoW | [18F]APN-1607 | APRINOIA Therapeutics | Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease, Healthy Volunteers | 06/23 | 06/23 | | |
NCT06750419: 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study |
|
|
| Recruiting | 3 | 82 | RoW | 89Zr-TLX250 PET/CT, 89Zr-DFO-girentuximab, 89Zr-girentuximab, 89Zr-DFO-TFP-GTX, 89Zirconium-labelled girentuximab | Telix Pharmaceuticals (Innovations) Pty Limited | Clear Cell Renal Cell Carcinoma | 06/26 | 06/26 | | |
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 110 | RoW | 68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET | Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd. | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 12/25 | 07/26 | | |
NCT05490849: 68Ga-HX01 PET in Healthy Volunteers and Malignant Tumors Patients |
|
|
| Recruiting | 1 | 100 | RoW | 68Ga-HX01, gallium-68 (68Ga)-HX01 | Wuhan Union Hospital, China | Malignant Neoplasm | 06/23 | 12/23 | | |
NCT06383520: Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 100 | RoW | 68Ga-aGPC3-scFv/Fab, gallium-68(68Ga)-aGPC3-scFv/Fab | Wuhan Union Hospital, China | Malignant Neoplasm of Liver | 12/24 | 12/25 | | |
NCT06190574: Diagnostic Efficacy and Prognostic Value of 18F-FDG PET/CT (MR) in Pediatric Solid Blastoma |
|
|
| Completed | N/A | 50 | RoW | Telephone follow-up | Wuhan Union Hospital, China | 18F-FDG, Neuroblastoma, Hepatoblastoma, Wilms Tumor | 09/23 | 11/23 | | |
NCT04005963: The Value of PET Quantitative Analysis of Coronary Physiology in Coronary Microvascular Disease |
|
|
| Active, not recruiting | N/A | 150 | RoW | 13N-NH3 PET cardiac blood flow perfusion rest and load imaging | Wuhan Union Hospital, China | PET / CT, Coronary Microvascular Disease | 12/21 | 12/23 | | |
NCT04982458: Visualized Monitoring of Fibrosis Formation in Heart Failure With 68GA-FAPI PET |
|
|
| Active, not recruiting | N/A | 50 | RoW | 68Ga-FAPI | Wuhan Union Hospital, China | Heart Failure, Positron Emission Tomography | 08/22 | 12/23 | | |
NCT04996927: 18F-FDG PET/CT to Evaluate pD-1 Monoclonal Antibody With First-line Chemotherapy in Advanced NSCLC |
|
|
| Recruiting | N/A | 50 | RoW | | Wuhan Union Hospital, China | NSCLC | 06/23 | 06/23 | | |
NCT03756077: A Study of the Value of Hybrid PET/MR and PET/CT in Prostate Cancer |
|
|
| Recruiting | N/A | 100 | RoW | 68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT | Wuhan Union Hospital, China | Prostate Cancer, PET/MR, PET/CT | 06/23 | 12/23 | | |
NCT05645484: The Prognostic Value of 18F-PFPN PET Imaging in Patients With Malignant Melanoma |
|
|
| Recruiting | N/A | 100 | RoW | 18F-PFPN, 18F-PEG3-FPN, 18F-FDG, 18F-fluorodeoxyglucose | Wuhan Union Hospital, China | Melanoma | 08/23 | 08/23 | | |
NCT05003830: Application of Multi-probe PET/MR Imaging in the Diagnosis and Evaluation of Alzheimer's Disease |
|
|
| Recruiting | N/A | 130 | RoW | PET/MR, Positron Emission Tomography/Magnetic Resonance | Wuhan Union Hospital, China | Alzheimer Disease, PET/MR | 09/23 | 09/23 | | |
NCT04006223: The Diagnostic Value of Hybrid PET/MR for Systemic Amyloidosis |
|
|
| Recruiting | N/A | 30 | RoW | 11C-PIB or 18F-florbetapir PET/MR before biopsy and treatment, 11C-PIB or 18F-florbetapir PET/MR after treatment | Wuhan Union Hospital, China | Systemic Amyloidosis, PET/MR | 12/23 | 12/23 | | |
NCT04045834: Study of the Diagnostic Value of Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor Induced Osteomalacia |
|
|
| Recruiting | N/A | 60 | RoW | 68Ga-DOTA-TATE PET/MR and PET/CT imaging | Wuhan Union Hospital, China | PET / CT, PET / MR, Neuroendocrine Tumors, Osteomalacia | 12/23 | 12/23 | | |
NCT04554719: Clinical Application of Fibroblast Activation Protein PET/MRI for Diagnosis and Staging in Malignant Tumors |
|
|
| Recruiting | N/A | 500 | RoW | 68Ga-DOTA-FAPI, gallium-68 (68Ga)-Fibroblast activation protein inhibitor (FAPI), PET/MR, Positron Emission Tomography/Magnetic Resonance, PET/CT, Positron Emission Tomography/Computed Tomography | Wuhan Union Hospital, China | Malignant Neoplasm | 12/23 | 12/23 | | |
NCT04605939: Clinical Application of Fibroblast Activation Protein PET/MRI in Liver Fibrosis |
|
|
| Recruiting | N/A | 100 | RoW | PET/MR, Positron Emission Tomography/Magnetic Resonance, PET/CT, Positron Emission Tomography/Computed Tomography | Wuhan Union Hospital, China | Liver Fibrosis, Positron Emission Tomography, Magnetic Resonance Imaging | 12/23 | 12/23 | | |
NCT04747561: Clinical Application of 18F-PEG3-FPN PET Imaging in Diagnosis and Staging of Malignant Melanoma |
|
|
| Recruiting | N/A | 50 | RoW | 18F-PEG3-FPN, 18F-FDG | Wuhan Union Hospital, China | Melanoma | 12/23 | 12/23 | | |
NCT05006326: Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 30 | RoW | 68Ga-PSMA, gallium-68 (68Ga)-prostate specific membrane antigen (PSMA), PET/MR, Positron Emission Tomography/Magnetic Resonance, PET/CT, Positron Emission Tomography/Computed Tomography | Wuhan Union Hospital, China | Malignant Neoplasm | 12/23 | 12/23 | | |
NCT05999227: 68Ga-FAPI-04 PET Imaging in Early Response Evaluation of Rectal Cancer Patients Treated With Immunotherapy |
|
|
| Recruiting | N/A | 20 | RoW | 68Ga-FAPI-04, 68Ga-FAPI, 18F-FDG, 18F-fluorodeoxyglucose | Wuhan Union Hospital, China | Rectal Cancer | 12/23 | 07/24 | | |
NCT05963035: Clinical Application of 18F-PFPN PET Imaging in Diagnosis and Staging of Clear Cell Sarcoma of Soft Tissue |
|
|
| Recruiting | N/A | 10 | RoW | 18F-PFPN, 18F-PEG3-FPN | Wuhan Union Hospital, China | Clear Cell Sarcoma of Soft Tissue | 12/23 | 06/24 | | |
